Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Dose-escalation Study Evaluating the Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy

NCT03424850 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT03424850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03424850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Dose-escalation Study Evaluating the Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy
Lead sponsor
Washington University School of Medicine
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 27, 2018
Completion date
February 28, 2030
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer, prostate neoplasm